Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner

Neurobiology of Aging

Volumn 36, Issue 4, 2015, Pages 1619-1628

  Gietl, Anton F ^a   Warnock, Geoffrey ^b   Riese, Florian ^a   Kälin, Andrea M ^a   Saake, Antje ^a   Gruber, Esmeralda ^a   Leh, Sandra E ^a   Unschuld, Paul G ^a   Kuhn, Felix P ^b   Burger, Cyrill ^b,c   Mu, Linjing ^b,d   Seifert, Burkhardt ^a   Nitsch, Roger M ^a   Schibli, Roger ^b,d   Ametamey, Simon M ^d   Buck, Alfred ^b   Hock, Christoph ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PMOD Technologies   (Switzerland)

^d ETH ZURICH   (Switzerland)

Author keywords

Aging; Alzheimer's disease; Amyloid; Biomarker; Cerebral blood flow; Frontal; Hippocampus; MCI; MRI; PET; PiB; Posterior cingulate cortex

Indexed keywords

APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; AMYLOID PROTEIN; ANILINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGE; AGED; AMYLOIDOSIS; APOE4 GENE; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; INFERIOR FRONTAL GYRUS; LEFT HEMISPHERE; MILD COGNITIVE IMPAIRMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAHIPPOCAMPAL GYRUS; PARIETAL GYRUS; POSTERIOR CINGULATE; PRIORITY JOURNAL; RIGHT HEMISPHERE; SUPERIOR PARIETAL GYRUS; AGING; ALLELE; BLOOD FLOW; BRAIN; COGNITION; FEMALE; GENETICS; GENOTYPE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALLELES; AMYLOIDOGENIC PROTEINS; ANILINE COMPOUNDS; APOLIPOPROTEIN E4; BRAIN; COGNITION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; REGIONAL BLOOD FLOW; THIAZOLES;

EID: 84925329106     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.12.036     Document Type: Article

References (82)

1. Aanerud J., Borghammer P., Chakravarty M.M., Vang K., Rodell A.B., Jonsdottir K.Y., Moller A., Ashkanian M., Vafaee M.S., Iversen P., Johannsen P., Gjedde A. Brain energy metabolism and blood flow differences in healthy aging. J.Cereb. Blood Flow Metab. 2012, 32:1177-1187.
2. Akinyemi R.O., Mukaetova-Ladinska E.B., Attems J., Ihara M., Kalaria R.N. Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Curr. Alzheimer Res. 2013, 10:642-653.
3. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C., Gamst A., Holtzman D.M., Jagust W.J., Petersen R.C., Snyder P.J., Carrillo M.C., Thies B., Phelps C.H. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:270-279.
4. Alsop D.C., Dai W., Grossman M., Detre J.A. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J.Alzheimers Dis. 2010, 20:871-880.
5. Anchisi D., Borroni B., Franceschi M., Kerrouche N., Kalbe E., Beuthien-Beumann B., Cappa S., Lenz O., Ludecke S., Marcone A., Mielke R., Ortelli P., Padovani A., Pelati O., Pupi A., Scarpini E., Weisenbach S., Herholz K., Salmon E., Holthoff V., Sorbi S., Fazio F., Perani D. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch. Neurol. 2005, 62:1728-1733.
6. Arendt T. Synaptic degeneration in Alzheimer's disease. Acta Neuropathol. 2009, 118:167-179.
7. Arnaiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001, 12:851-855.
8. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat. Neurosci. 2011, 14:750-756.
9. Blomquist G., Engler H., Nordberg A., Ringheim A., Wall A., Forsberg A., Estrada S., Frandberg P., Antoni G., Langstrom B. Unidirectional influx and net accumulation of PIB. Open Neuroimaging J. 2008, 2:114-125.
10. Braak H., Thal D.R., Ghebremedhin E., Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J.Neuropathol. Exp. Neurol. 2011, 70:960-969.
11. Brown W.R., Thore C.R. Review: cerebral microvascular pathology in ageing and neurodegeneration. Neuropathol. Appl. Neurobiol. 2011, 37:56-74.
12. Chetelat G., Desgranges B., de la Sayette V., Viader F., Eustache F., Baron J.C. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease?. Neurology 2003, 60:1374-1377.
13. Chung Y.A., O J.H., Kim J.Y., Kim K.J., Ahn K.J. Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT. J.Nucl. Med. 2009, 50:1969-1974.
14. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels invivo. Neuron 2005, 48:913-922.
15. Costafreda S.G., Fu C.H., Lee L., Everitt B., Brammer M.J., David A.S. Asystematic review and quantitative appraisal of fMRI studies of verbal fluency: role of the left inferior frontal gyrus. Hum. Brain Mapp. 2006, 27:799-810.
16. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10966-10971.
17. De Santi S., de Leon M.J., Rusinek H., Convit A., Tarshish C.Y., Roche A., Tsui W.H., Kandil E., Boppana M., Daisley K., Wang G.J., Schlyer D., Fowler J. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol. Aging 2001, 22:529-539.
18. Drzezga A., Grimmer T., Riemenschneider M., Lautenschlager N., Siebner H., Alexopoulus P., Minoshima S., Schwaiger M., Kurz A. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J.Nucl. Med. 2005, 46:1625-1632.
19. Drzezga A., Lautenschlager N., Siebner H., Riemenschneider M., Willoch F., Minoshima S., Schwaiger M., Kurz A. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur. J. Nucl. Med. Mol. Imaging 2003, 30:1104-1113.
20. Elman J.A., Oh H., Madison C.M., Baker S.L., Vogel J.W., Marks S.M., Crowley S., O'Neil J.P., Jagust W.J. Neural compensation in older people with brain amyloid-beta deposition. Nat. Neurosci. 2014, 17:1316-1318.
21. Forsberg A., Engler H., Blomquist G., Langstrom B., Nordberg A. The use of PIB-PET as a dual pathological and functional biomarker in AD. Biochim. Biophys. Acta 2012, 1822:380-385.
22. Fu L., Liu L., Zhang J., Xu B., Fan Y., Tian J. Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. Eur. Radiol. 2014, 24:2800-2809.
23. Giovacchini G., Squitieri F., Esmaeilzadeh M., Milano A., Mansi L., Ciarmiello A. PET translates neurophysiology into images: a review to stimulate a network between neuroimaging and basic research. J.Cell. Physiol. 2011, 226:948-961.
24. Gjedde A., Aanerud J., Braendgaard H., Rodell A.B. Blood-brain transfer of Pittsburgh compound B in humans. Front. Aging Neurosci. 2013, 5:70.
25. Gousias I.S., Rueckert D., Heckemann R.A., Dyet L.E., Boardman J.P., Edwards A.D., Hammers A. Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest. Neuroimage 2008, 40:672-684.
26. Hammers A., Allom R., Koepp M.J., Free S.L., Myers R., Lemieux L., Mitchell T.N., Brooks D.J., Duncan J.S. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum. Brain Mapp. 2003, 19:224-247.
27. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
28. Hasnain M., Victor R.V.W. Possible role of vascular risk factors in Alzheimer's disease and vascular dementia. Curr. Pharm. Des. 2014, 20:6007-6013.
29. Herholz K. Perfusion SPECT and FDG-PET. Int. Psychogeriatr. 2011, 23(Suppl 2):S25-S31.
30. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J.Lipid Res. 1990, 31:545-548.
31. Holm S. Asimple sequentially rejective multiple test procedure. Scand. J. Stat. 1979, 6:65-70.
32. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
33. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
34. Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron 2013, 77:219-234.
35. Katzev M., Tuscher O., Hennig J., Weiller C., Kaller C.P. Revisiting the functional specialization of left inferior frontal gyrus in phonological and semantic fluency: the crucial role of task demands and individual ability. J.Neurosci. 2013, 33:7837-7845.
36. Kellner V., Menkes-Caspi N., Beker S., Stern E.A. Amyloid-beta alters ongoing neuronal activity and excitability in the frontal cortex. Neurobiol. Aging 2014, 35:1982-1991.
37. Knopman D.S., Jack C.R., Wiste H.J., Lundt E.S., Weigand S.D., Vemuri P., Lowe V.J., Kantarci K., Gunter J.L., Senjem M.L., Mielke M.M., Roberts R.O., Boeve B.F., Petersen R.C. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol. Aging 2014, 35:2096-2106.
38. Landau S.M., Harvey D., Madison C.M., Reiman E.M., Foster N.L., Aisen P.S., Petersen R.C., Shaw L.M., Trojanowski J.Q., Jack C.R., Weiner M.W., Jagust W.J. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 2010, 75:230-238. Alzheimer's Disease Neuroimaging Initiative.
39. Leenders K.L., Perani D., Lammertsma A.A., Heather J.D., Buckingham P., Healy M.J., Gibbs J.M., Wise R.J., Hatazawa J., Herold S., Beaney R.P., Brooks D.J., Spinks T., Rhodes C., Frackowiak R.S.J. Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain 1990, 113(Pt 1):27-47.
40. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Nagren K., Kim B.C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
41. Liakakis G., Nickel J., Seitz R.J. Diversity of the inferior frontal gyrus-a meta-analysis of neuroimaging studies. Behav. Brain Res. 2011, 225:341-347.
42. Lowe V.J., Weigand S.D., Senjem M.L., Vemuri P., Jordan L., Kantarci K., Boeve B., Jack C.R., Knopman D., Petersen R.C. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014, 82:1959-1967.
43. Maier F.C., Wehrl H.F., Schmid A.M., Mannheim J.G., Wiehr S., Lerdkrai C., Calaminus C., Stahlschmidt A., Ye L., Burnet M., Stiller D., Sabri O., Reischl G., Staufenbiel M., Garaschuk O., Jucker M., Pichler B.J. Longitudinal PET-MRI reveals beta-amyloid deposition and rCBF dynamics and connects vascular amyloidosis to quantitative loss of perfusion. Nat. Med. 2014, 20:1485-1492.
44. Marchal G., Rioux P., Petit-Taboue M.C., Sette G., Travere J.M., Le Poec C., Courtheoux P., Derlon J.M., Baron J.C. Regional cerebral oxygen consumption, blood flow, and blood volume in healthy human aging. Arch. Neurol. 1992, 49:1013-1020.
45. Mattsson N., Tosun D., Insel P.S., Simonson A., Jack C.R., Beckett L.A., Donohue M., Jagust W., Schuff N., Weiner M.W. Association of brain amyloid-beta with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain 2014, 137(Pt 5):1550-1561. Alzheimer's Disease Neuroimaging, Initiative.
46. Meltzer C.C., Cantwell M.N., Greer P.J., Ben-Eliezer D., Smith G., Frank G., Kaye W.H., Houck P.R., Price J.C. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J.Nucl. Med. 2000, 41:1842-1848.
47. Merlini M., Meyer E.P., Ulmann-Schuler A., Nitsch R.M. Vascular beta-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAbeta mice. Acta Neuropathol. 2011, 122:293-311.
48. Mevel K., Desgranges B., Baron J.C., Landeau B., De la Sayette V., Viader F., Eustache F., Chetelat G. Detecting hippocampal hypometabolism in mild cognitive impairment using automatic voxel-based approaches. Neuroimage 2007, 37:18-25.
49. Meyer P.T., Hellwig S., Amtage F., Rottenburger C., Sahm U., Reuland P., Weber W.A., Hull M. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. J.Nucl. Med. 2011, 52:393-400.
50. Mielke M.M., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V.J., Roberts R.O., Geda Y.E., Swenson-Dravis D.M., Boeve B.F., Senjem M.L., Vemuri P., Petersen R.C., Jack C.R. Indicators of amyloid burden in a population-based study of cognitively normal elderly. Neurology 2012, 79:1570-1577.
51. Morin A., Michaud J. Self-awareness and the left inferior frontal gyrus: inner speech use during self-related processing. Brain Res. Bull. 2007, 74:387-396.
52. Mormino E.C., Brandel M.G., Madison C.M., Marks S., Baker S.L., Jagust W.J. Abeta deposition in aging is associated with increases in brain activation during successful memory encoding. Cereb. Cortex 2012, 22:1813-1823.
53. Mosconi L., Murray J., Tsui W.H., Li Y., Spector N., Goldowsky A., Williams S., Osorio R., McHugh P., Glodzik L., Vallabhajosula S., de Leon M.J. Brain imaging of cognitively normal individuals with 2 parents affected by late-onset AD. Neurology 2014, 82:752-760.
54. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63:2332-2340.
55. Mosconi L., Tsui W.H., De Santi S., Li J., Rusinek H., Convit A., Li Y., Boppana M., de Leon M.J. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology 2005, 64:1860-1867.
56. Mosconi L., Tsui W.H., Herholz K., Pupi A., Drzezga A., Lucignani G., Reiman E.M., Holthoff V., Kalbe E., Sorbi S., Diehl-Schmid J., Perneczky R., Clerici F., Caselli R., Beuthien-Baumann B., Kurz A., Minoshima S., de Leon M.J. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J.Nucl. Med. 2008, 49:390-398.
57. Mufson E.J., Ma S.Y., Cochran E.J., Bennett D.A., Beckett L.A., Jaffar S., Saragovi H.U., Kordower J.H. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J.Comp. Neurol. 2000, 427:19-30.
58. Nakagawa S., Cuthill I.C. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol. Rev. Camb. Philos. Soc. 2007, 82:591-605.
59. Nestor P.J., Fryer T.D., Smielewski P., Hodges J.R. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann. Neurol. 2003, 54:343-351.
60. Nobili F., Salmaso D., Morbelli S., Girtler N., Piccardo A., Brugnolo A., Dessi B., Larsson S.A., Rodriguez G., Pagani M. Principal component analysis of FDG PET in amnestic MCI. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2191-2202.
61. Oh H., Habeck C., Madison C., Jagust W. Covarying alterations in Abeta deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. 2014, 35:297-308.
62. Ostergaard L., Aamand R., Gutierrez-Jimenez E., Ho Y.C., Blicher J.U., Madsen S.M., Nagenthiraja K., Dalby R.B., Drasbek K.R., Moller A., Braendgaard H., Mouridsen K., Jespersen S.N., Jensen M.S., West M.J. The capillary dysfunction hypothesis of Alzheimer's disease. Neurobiol. Aging 2013, 34:1018-1031.
63. Paulson O.B., Hasselbalch S.G., Rostrup E., Knudsen G.M., Pelligrino D. Cerebral blood flow response to functional activation. J.Cereb. Blood Flow Metab. 2010, 30:2-14.
64. Peca S., McCreary C.R., Donaldson E., Kumarpillai G., Shobha N., Sanchez K., Charlton A., Steinback C.D., Beaudin A.E., Fluck D., Pillay N., Fick G.H., Poulin M.J., Frayne R., Goodyear B.G., Smith E.E. Neurovascular decoupling is associated with severity of cerebral amyloid angiopathy. Neurology 2013, 81:1659-1665.
65. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:284-289.
66. Riese F., Gietl A., Zolch N., Henning A., O'Gorman R., Kalin A.M., Leh S.E., Buck A., Warnock G., Edden R.A., Luechinger R., Hock C., Kollias S., Michels L. Posterior cingulate gamma-aminobutyric acid and glutamate/glutamine are reduced in amnestic mild cognitive impairment and are unrelated to amyloid deposition and apolipoprotein E genotype. Neurobiol. Aging 2015, 36:53-59.
67. Rostomian A.H., Madison C., Rabinovici G.D., Jagust W.J. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J.Nucl. Med. 2011, 52:173-179.
68. Scarmeas N., Habeck C.G., Stern Y., Anderson K.E. APOE genotype and cerebral blood flow in healthy young individuals. JAMA 2003, 290:1581-1582.
69. Scheff S.W., Price D.A., Schmitt F.A., Scheff M.A., Mufson E.J. Synaptic loss in the inferior temporal gyrus in mild cognitive impairment and Alzheimer's disease. J.Alzheimers Dis. 2011, 24:547-557.
70. Schreiner S.J., Liu X., Gietl A.F., Wyss M., Steininger S.C., Gruber E., Treyer V., Meier I.B., Kalin A.M., Leh S.E., Buck A., Nitsch R.M., Pruessmann K.P., Hock C., Unschuld P.G. Regional fluid-attenuated inversion recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects. Front. Aging Neurosci. 2014, 6:240.
71. Solbach C., Uebele M., Reischl G., Machulla H.J. Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's disease with PET. Appl. Radiat. Isot. 2005, 62:591-595.
72. Sperling R.A., Aisen P.S., Beckett L.A., Bennett D.A., Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7:280-292.
73. Sperling R.A., Laviolette P.S., O'Keefe K., O'Brien J., Rentz D.M., Pihlajamaki M., Marshall G., Hyman B.T., Selkoe D.J., Hedden T., Buckner R.L., Becker J.A., Johnson K.A. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009, 63:178-188.
74. Steininger S.C., Liu X., Gietl A., Wyss M., Schreiner S., Gruber E., Treyer V., Kalin A., Leh S., Buck A., Nitsch R.M., Prussmann K.P., Hock C., Unschuld P.G. Cortical amyloid beta in cognitively normal elderly adults is associated with decreased network efficiency within the cerebro-cerebellar system. Front. Aging Neurosci. 2014, 6:52.
75. Takada H., Nagata K., Hirata Y., Satoh Y., Watahiki Y., Sugawara J., Yokoyama E., Kondoh Y., Shishido F., Inugami A. Age-related decline of cerebral oxygen metabolism in normal population detected with positron emission tomography. Neurol. Res. 1992, 14(2 Suppl):128-131.
76. Thal D.R., Griffin W.S., de Vos R.A., Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008, 115:599-609.
77. Thambisetty M., Beason-Held L., An Y., Kraut M.A., Resnick S.M. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging. Arch. Neurol. 2010, 67:93-98.
78. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., Hasselbalch S., Law I., Andersen A., Korner A., Minthon L., Garraux G., Nelissen N., Bormans G., Buckley C., Owenius R., Thurfjell L., Farrar G., Brooks D.J. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 2010, 68:319-329.
79. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367.
80. Wierenga C.E., Clark L.R., Dev S.I., Shin D.D., Jurick S.M., Rissman R.A., Liu T.T., Bondi M.W. Interaction of age and APOE genotype on cerebral blood flow at rest. J.Alzheimers Dis. 2013, 34:921-935.
81. Winblad B., Palmer K., Kivipelto M., Jelic V., Fratiglioni L., Wahlund L.O., Nordberg A., Backman L., Albert M., Almkvist O., Arai H., Basun H., Blennow K., de Leon M., DeCarli C., Erkinjuntti T., Giacobini E., Graff C., Hardy J., Jack C., Jorm A., Ritchie K., van Duijn C., Visser P., Petersen R.C. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J.Intern. Med. 2004, 256:240-246.
82. Zhang S., Han D., Tan X., Feng J., Guo Y., Ding Y. Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment. Int. J. Clin. Pract. 2012, 66:185-198.